Zobrazeno 1 - 10
of 27
pro vyhledávání: '"D T Rubin"'
Autor:
B Sands, L Peyrin-Biroulet, S Danese, D T Rubin, S Vermeire, O Laurent, A Luo, D Nguyen, J D Lu, A Wiechowska-Kozlowska, J Leszczyszyn, R Kempinski, J Kierkus, C Ma, T Ritter, B G Feagan, S Targan
Publikováno v:
Journal of Crohn's and Colitis. 17:i56-i59
Background Tumor necrosis factor-like cytokine 1A (TL1A) is an upstream regulator of pro-inflammatory cytokines and fibrosis signals. PRA023 is an anti-TL1A monoclonal antibody in development for multiple inflammatory/fibrotic diseases using a precis
Autor:
D T Rubin, J Panés, J Torres, T Kobayashi, C Su, N Lawendy, I Modesto, M Segovia, S Gardiner, W Wang, S Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 17:i914-i916
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. The long-term, Phase 3b/4 RIVETING study (NCT03281304) assessed the efficacy and safety of tofacitinib dose reduction from tofacitinib 10
Autor:
G D'Haens, J Tran, S Danese, D T Rubin, N Aoyama, A Lügering, J Klaff, S Xuan, D Ilo, Y Sanchez Gonzalez, J Panes
Publikováno v:
Journal of Crohn's and Colitis. 17:i27-i29
Background Abdominal pain (AP), bowel urgency (BU), stool frequency (SF), rectal bleeding (RB) and fatigue are debilitating symptoms that reduce quality of life in patients with ulcerative colitis (UC). Results from two Phase 3 induction trials and o
Autor:
L Peyrin-Biroulet, G Parkes, C Rodríguez, J Siffledeen, J Wright, E Broide, S Ford, A P Lacerda, J Oomen, A Garrison, S Berg, D T Rubin
Publikováno v:
Journal of Crohn's and Colitis. 17:i20-i22
Background Biologic therapies are used to treat moderate-to-severe Crohn’s Disease (CD), but many patients eventually lose response to them. With new potential therapies for CD, understanding their efficacy after patients undergo biologic treatment
Autor:
S Friedberg, D Choi, T Hunold, N K Choi, N M Garcia, E A Picker, N A Cohen, R D Cohen, S R Dalal, J Pekow, A Sakuraba, N Krugliak Cleveland, D T Rubin
Publikováno v:
Journal of Crohn's and Colitis. 17:i707-i709
Background Upadacitinib (upa) is a novel selective JAK-1 inhibitor that has demonstrated efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) and has received regulatory approval for UC. We report a large
Autor:
S Friedberg, D Choi, T Hunold, N K Choi, N M Garcia, E A Picker, N A Cohen, R D Cohen, S R Dalal, J Pekow, A Sakuraba, N K Cleveland, D T Rubin
Publikováno v:
Journal of Crohn's and Colitis. 17:i931-i933
Background Upadacitinib (upa) is a novel selective JAK-1 inhibitor that has demonstrated efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) and has received regulatory approval for UC. We report our pro
Autor:
S Vermeire, A Yarur, D T Rubin, M C Dubinsky, M Regueiro, P Irving, L Peyrin-Biroulet, M Goetsch, G Gu, J Wu, I Modesto, A McDonnell, C J Rabbat, J Green, P Anthopoulos
Publikováno v:
Journal of Crohn's and Colitis. 17:i604-i606
Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). First-dose, transient heart
Autor:
N Krugliak Cleveland, S Friedberg, D Choi, T Hunold, N K Choi, N M Garcia, E A Picker, N A Cohen, R D Cohen, S R Dalal, J Pekow, A Sakuraba, D T Rubin
Publikováno v:
Journal of Crohn's and Colitis. 17:i854-i856
Background The development and availability of Janus kinus inhibitors (JAKinibs) for moderately to severely active ulcerative colitis (UC) provides new therapeutic options with both novel mechanisms and unique pharmacodynamic benefits. Tofacitinib (t
Autor:
L Biedermann, M C Dubinsky, S Vermeire, M Fellmann, S Gardiner, P Hur, R Mundayat, J Panés, D T Rubin
Publikováno v:
Journal of Crohn's and Colitis. 16:i317-i319
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Tofacitinib induction and maintenance therapy has previously been shown to improve health-related quality of life (HRQoL) outcomes. Here, we
Autor:
S Danese, J Tran, G D’Haens, D T Rubin, N Aoyama, W Zhou, B James, X Yao, Y SanchezGonzalez, R Panaccione
Publikováno v:
Journal of Crohn's and Colitis. 16:i008-i010
Background Abdominal pain (AP), bowel urgency (BU), and fatigue are debilitating symptoms that reduce quality of life in patients with active ulcerative colitis (UC). Results from two Phase 3 induction trials (U-ACHIEVE induction [NCT02819635] and U-